m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00293)
Target Name Interleukin-11 (IL11)
Gene Name IL11
Chromosomal Location 19q13.42
Family IL-6 superfamily
Function
Cytokine that stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production. Also promotes the proliferation of hepatocytes in response to liver damage. Binding to its receptor formed by IL6ST and IL11RA activates a signaling cascade that promotes cell proliferation. Signaling leads to the activation of intracellular protein kinases and the phosphorylation of STAT3. The interaction with the membrane-bound IL11RA and IL6ST stimulates 'classic signaling', whereas the binding of IL11 and soluble IL11RA to IL6ST stimulates 'trans-signaling'.
    Click to Show/Hide
Gene ID 3589
Uniprot ID
IL11_HUMAN
HGNC ID
HGNC:5966
Ensembl Gene ID
ENSG00000095752
KEGG ID
hsa:3589
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
IL11 can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
YTH domain-containing family protein 2 (YTHDF2) [READER]
 Regulator Info 
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary YTHDF2 processed the decay of m6A-containing Interleukin-11 (IL11) and serpin family E member 2 (SERPINE2) mRNAs. YTHDF2 transcription succumbed to hypoxia-inducible factor-2-alpha (HIF-2-alpha). Administration of a HIF-2-alpha antagonist (PT2385) restored YTHDF2-programed epigenetic machinery and repressed liver cancer.
Target Regulation Down regulation
Responsed Disease Hepatocellular carcinoma ICD-11: 2C12.02
 Disease Info 
Pathway Response HIF-1 signaling pathway hsa04066
Cell Process Biological regulation
In-vitro Model MHCC97-H Adult hepatocellular carcinoma Homo sapiens CVCL_4972
SMMC-7721 Endocervical adenocarcinoma Homo sapiens CVCL_0534
In-vivo Model A number of 5 × 106 SMMC7721 or MHCC97H cells re-suspended in 100 uL of PBS were subcutaneously injected into the right flank of 6-week old male NCG mice.
Liver cancer [ICD-11: 2C12]
 Disease Info 
In total 1 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary YTHDF2 processed the decay of m6A-containing Interleukin-11 (IL11) and serpin family E member 2 (SERPINE2) mRNAs. YTHDF2 transcription succumbed to hypoxia-inducible factor-2-alpha (HIF-2-alpha). Administration of a HIF-2-alpha antagonist (PT2385) restored YTHDF2-programed epigenetic machinery and repressed liver cancer.
Responsed Disease Hepatocellular carcinoma [ICD-11: 2C12.02]
Target Regulator YTH domain-containing family protein 2 (YTHDF2) READER
 Regulator Info 
Target Regulation Down regulation
Pathway Response HIF-1 signaling pathway hsa04066
Cell Process Biological regulation
In-vitro Model MHCC97-H Adult hepatocellular carcinoma Homo sapiens CVCL_4972
SMMC-7721 Endocervical adenocarcinoma Homo sapiens CVCL_0534
In-vivo Model A number of 5 × 106 SMMC7721 or MHCC97H cells re-suspended in 100 uL of PBS were subcutaneously injected into the right flank of 6-week old male NCG mice.
References
Ref 1 YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma. Mol Cancer. 2019 Nov 18;18(1):163. doi: 10.1186/s12943-019-1082-3.